Twist Bioscience Corp Chief Financial Officer Adam Laponis filed a Form 4 on November 16, 2026, disclosing the acquisition of 26,746 Performance Stock Units on November 12, 2026, following a determination that target criteria had been met.
Key Highlights
- Reporting person: Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (NASDAQ:TWST)
- Transaction date: November 12, 2026, the date target criteria for the Performance Stock Units were determined to have been met
- Shares acquired: 26,746 shares of Common Stock via transaction code "A" (acquired) at a price of $0
- Partial time-based vesting remains: 60% of the PSUs remain subject to time-based vesting and will vest on September 30, 2027, subject to continued service, according to the filing
- Beneficial ownership following transaction: 124,860 shares of Common Stock held directly
- Filing signed by: Kendra Fox, as Attorney-in-Fact for Adam Laponis, on November 16, 2026
Twist Bioscience CFO Laponis PSU Award Details
According to the Form 4 filed with the SEC, Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (NASDAQ:TWST), reported the acquisition of 26,746 shares of Common Stock on November 12, 2026. The filing states the shares represent Performance Stock Units for which the target criteria was determined to have been met on that date. The transaction was coded "A" (acquired) at a price of $0, indicating no cash consideration was paid by the reporting person at the time of acquisition.
The filing notes that 60% of the PSUs remain subject to time-based vesting and will vest on September 30, 2027, subject to continued service. This means a portion of the 26,746 units reported will not convert unconditionally until that future date, contingent on the conditions described in the filing. Following the reported transaction, Laponis directly beneficially owned 124,860 shares of Twist Bioscience Common Stock, as stated in the filing.
The Form 4 was filed on November 16, 2026, with the date of the earliest transaction listed as November 12, 2026. The form was signed by Kendra Fox as Attorney-in-Fact for Adam Laponis. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
Twist Bioscience CFO Adam Laponis reported the acquisition of 26,746 Performance Stock Units at $0, with target criteria met on November 12, 2026. A portion remains subject to time-based vesting through September 30, 2027. Post-transaction direct beneficial ownership stands at 124,860 shares.




Please wait processing your request...